MetrionAIIntelligence

Sign in Register

Home Watchlist Market News High Impact News Market Movers Screener Portfolio Calculators Heatmap Compare Calendars Crypto Forex Macro Maps

Research Tools

Financial Analysis Analyst Estimates Insider Trading Market Guide Trading Ideas Charts

Financial Analysis

Highlights Income Statement Balance Sheet Cash Flow Multiples Profitability

Loading market dashboard

My Watchlist

Sign in to track securities

Create an account to keep a persistent watchlist.

Home High Impact News Market Movers

Loading news article

Back to markets

zacks.com/April 20, 2026 at 11:20 AMANIP

ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics

ANIP eyes 2026 growth via Cortrophin's gout push and steady generics launches, as Rare Disease expansion reshapes priorities and investor focus.

Open original source